2024 World Conference on Lung Cancer (WCLC) - Posters-P2.14A.10 Real-World Evidence of Ipilimumab Plus Nivolumab Combination Therapy in Patients with Malignant Pleural Mesothelioma

P2.14A.10 Real-World Evidence of Ipilimumab Plus Nivolumab Combination Therapy in Patients with Malignant Pleural Mesothelioma

Back to course

Pdf Summary

This study evaluates the safety and effectiveness of ipilimumab plus nivolumab combination therapy in 55 patients with malignant pleural mesothelioma (MPM) in a real-world clinical setting in Japan, following its approval in 2021. The analysis focuses on objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and immune-related adverse events (irAEs).<br /><br />The study population's median age was 72, with a substantial portion aged 75 or older, reflecting a real-world scenario with patients often having poorer tolerance to anticancer drugs. The ORR was found to be 40% and DCR 81.8%, comparable to the CheckMate-743 trial results, which initially supported the combination therapy's approval. The study reported a median PFS of 12.4 months, potentially longer than previously observed in clinical trials.<br /><br />Interestingly, patients over 80 contributed notably to longer PFS, possibly due to their better performance status (PS), which correlates strongly with improved outcomes. Additionally, the occurrence of irAEs was linked to prolonged PFS, consistent with trends observed across various cancers, including lung cancer. Grade 3-4 irAEs were present in 32.7% of cases, aligning with the original trial's findings, and skin rash emerged as the most frequent irAE.<br /><br />Overall, this real-world study indicates that the ipilimumab and nivolumab combination is an effective and safe treatment option for MPM, particularly for patients with good PS who may not tolerate cisplatin. The authors observed no treatment-related deaths and reported that irAEs correlate with better clinical outcomes, specifically improved PFS. This demonstrates the potential benefit of ICIs in practical settings and highlights their viability as an alternative to conventional chemotherapy for MPM.

Asset Subtitle

Takanori Kondo

Meta Tag

Speaker Takanori Kondo

Topic Mesothelioma, Thymoma & Other Thoracic Tumors

Keywords

ipilimumab

nivolumab

malignant pleural mesothelioma

real-world study

objective response rate

disease control rate

progression-free survival

immune-related adverse events

CheckMate-743 trial

performance status